OAM
WVE icon

Oxford Asset Management’s Wave Life Sciences WVE Stock Holding History

Oxford Asset Management’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,045
Closed -$50.7K – 373
2023
Q4 		$50.7K Buy
+10,045
New +$53.7K 0.08% 176

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Oxford Asset Management's WVE Position: Q1 2024 in Review

Oxford Asset Management sold out of Wave Life Sciences (WVE) in Q1 2024, closing a stake of 10,045 shares — an estimated $50.7K sold.

Oxford Asset Management first reported a position in WVE in Q4 2023 and held it in 1 quarter. The position peaked at $50.7K in Q4 2023. 132 funds tracked by Wall St. Rank hold WVE as of Q1 2024.

  • Oxford Asset Management reported no remaining Wave Life Sciences position as of Q1 2024 after selling out during the quarter.
  • Oxford Asset Management sold 10,045 Wave Life Sciences shares in Q1 2024, an estimated $50.7K.
  • Oxford Asset Management first reported a position in Wave Life Sciences in Q4 2023 and held it in 1 quarter.
  • Oxford Asset Management's Wave Life Sciences position peaked at $50.7K in Q4 2023.
  • 132 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2024.

Based on Oxford Asset Management's 13F filing for Q1 2024, filed 15 May 2024.